Senores Pharmaceuticals Limited — Quarter and year ended March 31, 2026
Optional commentary: Extracted financial tables from the provided quarterly results document (Annexure-A and standalone/consolidated statements).
| Sr No. | Particulars | Quarter Ended March 31, 2026 Audited | Quarter Ended December 31, 2025 Unaudited | Year Ended March 31, 2025 Audited | Year Ended March 31, 2026 Audited | Year Ended March 31, 2025 Audited |
|---|---|---|---|---|---|---|
| 1 | Revenue from operations | 175.19 | 170.96 | 114.21 | 632.63 | 398.25 |
| 2 | Other Income | 17.67 | 7.39 | 11.77 | 47.06 | 19.26 |
| 3 | Total Income (1+2) | 192.86 | 178.34 | 125.98 | 679.69 | 417.51 |
| 4 | Expenses | |||||
| Cost of materials consumed | 27.05 | 36.96 | 20.94 | 114.27 | 91.64 | |
| Purchases of stock-in-trade | 35.71 | 37.87 | 29.06 | 137.32 | 89.82 | |
| Changes in inventories of finished goods, work-in-progress and stock-in-trade | 3.46 | (7.81) | 7.46 | 0.07 | (0.76) | |
| Employee benefits expenses | 30.32 | 30.66 | 14.63 | 112.25 | 60.37 | |
| Finance costs | 8.46 | 5.33 | 5.30 | 25.03 | 21.55 | |
| Depreciation & Amortisation expenses | 9.30 | 7.86 | 5.23 | 31.25 | 16.84 | |
| Other expenses | 31.16 | 22.87 | 22.68 | 100.40 | 67.48 | |
| Total expenses | 145.46 | 133.74 | 105.30 | 520.59 | 346.94 | |
| 5 | Profit before Tax (3-4) | 47.40 | 44.60 | 20.68 | 159.10 | 70.57 |
| 6 | Tax expense | |||||
| Current tax | (4.97) | 8.64 | 6.73 | 19.94 | 15.56 | |
| Deferred tax | 15.70 | 2.38 | (4.02) | 17.63 | (3.33) | |
| Total Tax Expense | 10.73 | 11.02 | 2.71 | 37.57 | 12.23 | |
| 7 | Net Profit after tax (5-6) | 36.67 | 33.58 | 17.97 | 121.53 | 58.34 |
| 8 | Other Comprehensive Income | |||||
| A (i) Items that will not be reclassified subsequently to profit or loss | 0.24 | (0.12) | (0.27) | (0.02) | (0.38) | |
| (ii) Income tax relating to items that will not be reclassified to profit and loss | (0.08) | 0.03 | 0.03 | (0.01) | 0.06 | |
| B (i) Items that will be reclassified subsequently to profit or loss | 41.76 | (4.70) | 0.13 | 29.22 | (3.21) | |
| (ii) Income tax relating to items that will be reclassified to profit and loss | – | – | – | – | – | |
| Total Other Comprehensive Income | 41.92 | (4.79) | (0.12) | 29.19 | (3.53) | |
| 9 | Total Comprehensive Income (7+8) | 78.59 | 28.79 | 17.85 | 150.72 | 54.82 |
| 10 | Profit for the period attributable to | |||||
| Equity Holders of the Company | 31.61 | 31.66 | 17.83 | 115.38 | 58.57 | |
| Non-Controlling Interest | 5.06 | 1.92 | 0.14 | 6.16 | (0.22) | |
| Other Comprehensive Income attributable to | ||||||
| Equity Holders of the Company | 36.95 | (3.64) | (0.28) | 26.96 | (3.07) | |
| Non-Controlling Interest | 4.97 | (1.15) | 0.16 | 2.23 | (0.46) | |
| Total Comprehensive Income attributable to | ||||||
| Equity Holders of the Company | 68.56 | 28.02 | 17.55 | 142.34 | 55.50 | |
| Non-Controlling Interest | 10.03 | 0.77 | 0.30 | 8.39 | (0.68) | |
| 11 | Paid up Equity Share Capital (Face Value Rs 10 per share) | 46.05 | 46.05 | |||
| 12 | Other Equity | 887.55 | 740.13 | |||
| 13 | Earnings per share (Face Value Rs 10 per share) (Not annualised for the quarter) | |||||
| Basic | 7.96 | 7.29 | 3.81 | 26.39 | 16.12 | |
| Diluted | 7.96 | 7.29 | 3.81 | 26.39 | 16.12 |
| Particulars | March 31, 2026 (Audited) | March 31, 2025 (Audited) |
|---|---|---|
| A ASSETS | ||
| 1 Non-current assets | ||
| Property, Plant and Equipment | 331.37 | 198.85 |
| Capital work-in-progress | 17.46 | 44.17 |
| Goodwill | 46.55 | 38.21 |
| Other Intangible assets | 106.79 | 54.27 |
| Intangible Assets under Development | 232.00 | 128.33 |
| Right of Use Assets | 13.88 | 9.36 |
| Investment property | 24.60 | – |
| Financial Assets | ||
| Investments | – | 4.29 |
| Other Financial Assets | 10.22 | 5.18 |
| Deferred Tax Assets (net) | – | 18.67 |
| Other Non-Current Assets | 4.22 | 7.38 |
| Total Non Current Assets | 791.38 | 504.43 |
| 2 Current assets | ||
| Inventories | 89.29 | 56.63 |
| Financial Assets | ||
| Trade Receivable | 324.82 | 123.89 |
| – Cash and cash equivalents | 45.55 | 105.38 |
| – Bank Balance other than above | 114.06 | 280.12 |
| – Other Financial Assets | 172.68 | 116.96 |
| Other current assets | 66.03 | 39.45 |
| Total Current Assets | 812.43 | 722.43 |
| TOTAL ASSETS (1+2) | 1,603.81 | 1,226.86 |
| Particulars | March 31, 2026 (Audited) | March 31, 2025 (Audited) |
|---|---|---|
| B EQUITY AND LIABILITIES | ||
| 1 Equity | ||
| Share capital | 46.05 | 46.05 |
| Other Equity | 887.55 | 740.13 |
| Equity Attributable to Equity Holders of the Parent | 933.60 | 786.18 |
| Non – Controlling Interests | 30.94 | 26.06 |
| Total Equity | 964.54 | 812.24 |
| Liabilities | ||
| Non-current liabilities | ||
| Financial Liabilities | ||
| Borrowings | 194.89 | 162.46 |
| Lease Liabilities | 13.18 | 8.20 |
| Provisions | 6.61 | 3.26 |
| Deferred tax liabilities (net) | 0.59 | – |
| Total Non Current Liabilities | 215.27 | 173.92 |
| 2 Current liabilities | ||
| Financial Liabilities | ||
| Borrowings | 132.20 | 142.30 |
| Lease Liabilities | 1.76 | 1.79 |
| Trade payables | ||
| (A) Dues to Micro and Small Enterprises | 11.90 | 15.50 |
| (B) Dues to Other than Micro and Small Enterprises | 222.82 | 51.73 |
| Other Financial Liabilities | 17.59 | 7.81 |
| Other current liabilities | 14.79 | 6.02 |
| Provisions | 2.71 | 2.06 |
| Current Tax Liabilities (Net) | 20.23 | 13.49 |
| Total Current Liabilities | 424.00 | 240.70 |
| TOTAL EQUITY AND LIABILITIES (1+2) | 1,603.81 | 1,226.86 |
| Particulars | March 31, 2026 (Audited) | March 31, 2025 (Audited) |
|---|---|---|
| (A) Cash Flow from Operating Activities: | ||
| Profit Before Tax | 159.10 | 70.57 |
| Adjustments for: | ||
| Depreciation & Amortisation expense | 31.25 | 16.84 |
| Interest Income | (14.00) | (7.16) |
| Finance Cost | 24.07 | 19.55 |
| Interest on Lease Liability | 0.96 | 0.81 |
| Deferred tax through Business Combinations | 0.58 | – |
| Profit on sale of Fixed Assets | (0.10) | – |
| Gain on account of translating financial statements of Foreign Subsidiaries | 15.23 | (2.94) |
| Operating Profit Before Working Capital Changes | 217.09 | 97.68 |
| Movement in Working Capital | ||
| Adjustments for decrease / (increase) in Assets | ||
| Inventories | (30.34) | (19.26) |
| Trade Receivables | (197.34) | (11.88) |
| Other Financial Assets | (60.45) | (34.82) |
| Other Non-Current Assets | 3.42 | (4.01) |
| Other Current Assets | (23.61) | (24.70) |
| Adjustments for (decrease) / increase in Liabilities | ||
| Trade Payables | 160.53 | (45.79) |
| Other Financial Liabilities | (4.65) | 2.74 |
| Other Current Liabilities | 7.14 | 0.98 |
| Provisions | 3.45 | 2.31 |
| Cash Generated from Operations | 75.25 | (36.75) |
| Direct Taxes Paid (Net) | (13.20) | (9.17) |
| Net Cash generated / (utilised) from Operating Activities (A) | 62.05 | (45.92) |
| (B) Cash Flow from Investing Activities: | ||
| Payments for property, plant and equipment, intangible assets and capital work in progress | (264.73) | (157.52) |
| Proceeds from sales / disposal of property, plant and equipment | 0.18 | – |
| Decrease / (Increase) in Loans | – | 0.33 |
| Acquisition of shares in existing Foreign Subsidiaries | (20.40) | (3.69) |
| Acquisition of shares in Domestic Subsidiary | (11.45) | – |
| Proceeds / (investment) in Bank deposits having maturity more than three months but less than twelve months | 166.13 | (275.76) |
| Increase in Investments in other shares & securities (Net) | (4.28) | – |
| Interest Received | 14.00 | 7.16 |
| Net Cash utilised in Investing Activities (B) | (120.56) | (429.48) |
| (C) Cash Flow from Financing Activities: | ||
| Proceeds from Issue of Equity Share Capital | – | 15.55 |
| Proceeds from Premium on Issue of Equity Share Capital (Net of Share issue expenses) | (1.91) | 456.21 |
| Proceeds from Issue of Equity Share Warrants (Net) | 23.62 | – |
| Proceeds from Long Term Borrowings (Net) | 12.74 | 28.81 |
| Increase /(decrease) in Lease Liabilities | 4.94 | 0.73 |
| Proceeds/(Repayment) from Short Term Borrowings | (15.68) | 92.20 |
| Interest on Lease Liability | (0.96) | (0.81) |
| Finance Cost paid | (24.07) | (19.55) |
| Net Cash generated / (utilised) in Financing Activities (C) | (1.33) | 573.13 |
| Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C) | (59.84) | 97.73 |
| Cash and Cash Equivalents as at beginning of the year | 105.38 | 7.65 |
| Add: Cash & Bank Acquired in Business Combinations | 0.01 | – |
| Cash and Cash Equivalents as at end of the period | 45.55 | 105.38 |
| Sr No. | Item Head | Amount as proposed in the Offer Document and as Revised | Amount utilized till March 31, 2026 | Amount unutilized as on March 31, 2026 | Remarks |
|---|---|---|---|---|---|
| 1 | Investment in one of our Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility | 107.00 | 6.98 | 100.02 | |
| 2 | Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company (Refer Note A below) | 73.10 | 73.10 | 0.00 | |
| 3 | Investment in our Subsidiary, namely, Havix, for re-payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries | 20.20 | 20.20 | 0.00 | Out of the unutilized amount, Rs. 4.00 crores parked as Fixed Deposit with HDFC Bank, Rs 100.45 crores parked as Fixed Deposit with ICICI Bank and the balance Rs. 0.57 crores held in HDFC bank account. |
| 4 | Funding the working capital requirements of our Company |